Last updated: February 25, 2026
What is TESSALON?
TESSALON is a brand name for the formulation of benzonatate, a non-narcotic antitussive used to suppress cough. Approved by the FDA in 1952, it is available in capsule form and primarily marketed in the United States. TESSALON's patent protection has long expired, making it a genericized product with ongoing opportunities in formulation and delivery modifications.
What are the key excipients in TESSALON?
The formulation of TESSALON capsules typically comprises:
- Active Ingredient: Benzonatate (200 mg per capsule).
- Capsule Shell: Gelatin.
- Fillers and Diluents: Lactose monohydrate is commonly used to fill capsules.
- Colorants: Titanium dioxide and iron oxide for capsule coloring.
- Preservatives: Some formulations may include small amounts of preservatives, although not universally.
The gelatin capsule shell is the primary excipient component that determines its physical form and stability.
What are strategic considerations for excipient choices?
-
Bioavailability and Release Profile:
- Benzonatate is a local anesthetic that acts peripherally; excipients that influence dissolution rates are less critical but may impact onset.
- Modified-release formulations could leverage osmotic agents or specialized polymers for extended effect.
-
Capsule Stability and Shelf Life:
- The gelatin shell must withstand humidity and temperature variations.
- Use of cross-linked gelatin or alternative hydroxypropyl methylcellulose (HPMC) capsules could improve stability, especially for markets with high humidity.
-
Patient Acceptance and Compliance:
- Blue or red capsules increase brand recognition.
- Flavoring agents or coating modifications could improve patient acceptance.
-
Manufacturing Compatibility:
- Excipients must be compatible with high-speed capsule filling machinery.
- Use of inert excipients like lactose prevents interactions with active ingredients.
-
Market-specific Regulations:
- Vegetarian or Halal/Kosher capsule options expand accessibility.
- Excipient sourcing must comply with regulatory standards (e.g., EFSA, FDA).
What are the commercial opportunities related to excipient strategies?
1. Formulation Innovation
- Extended-release TESSALON: Incorporating rate-controlling polymers (e.g., ethylcellulose) into the capsule or coating could allow for once-daily dosing, aligning with patient convenience.
- 替代船項: Vegetarians prefer HPMC capsules over gelatin, which can open markets in Europe, Asia, and among specific patient groups in the U.S.
2. Delivery Platform Enhancement
- Oral Thin Films: Developing sublingual or buccal films that contain benzonatate can bypass gastrointestinal degradation and improve onset.
- Innovative Carriers: Liposomal encapsulation or nanocarriers can enhance tissue targeting, potentially reducing side effects.
3. Regulatory and Supply Chain Differentiation
- Sourcing high-quality excipients ensures consistent manufacturing and regulatory compliance.
- Developing formulations with excipients compliant with multiple regulatory bodies increases marketability globally.
4. Market Diversification
- Low-cost Generics: Optimizing excipient costs in capsule production can improve margins in competing against generics.
- Specialty Market Positioning: Formulations with excipients suited for pediatric or geriatric populations, such as age-appropriate capsules or palatable formulations, expand reach.
5. Patent and Exclusivity Strategies
- While benzonatate patents expired, formulation patents involving novel excipient combinations or delivery systems can extend market exclusivity.
Regulatory and supply chain considerations
- Regulatory approval for excipient modifications requires appropriate stability, bioequivalence, and safety data.
- Supply chains for excipients like gelatin or HPMC must meet GMP standards, with potential risks from raw material shortages or contamination.
Summary table of excipient strategies
| Strategy |
Purpose |
Key Excipients |
Market Focus |
Challenges |
| Extended-release formulations |
Improve dosing convenience |
Ethylcellulose, hydroxypropyl methylcellulose |
Chronic cough, elderly |
Regulatory approval, sustaining release stability |
| Vegetarian capsules |
Market expansion |
HPMC or other non-gelatin capsules |
Europe, religious groups |
Cost, scalability |
| Novel delivery systems |
Faster onset, better compliance |
Liposomes, films |
Pediatric, special populations |
Technology development, regulatory hurdles |
| Cost optimization |
Competitive pricing |
Lactose, titanium dioxide |
Generics |
Raw material pricing, quality control |
Key Takeaways
- TESSALON's core excipient is gelatin, but opportunities exist to modify or substitute excipients to improve stability, compliance, and market access.
- Formulation innovations such as extended-release capsules or non-gelatin alternatives have commercial potential.
- Regulatory strategies must account for excipient changes, especially for novel delivery formats.
- Cost-effective excipient sourcing and supply chain resilience support competitive manufacturing.
- Market diversification through tailored formulations can increase market share in niche populations.
Frequently Asked Questions
1. Can the excipient profile of TESSALON be altered without losing bioequivalence?
Yes. Changes such as capsule shell material (gelatin to HPMC) or release-modifying agents require bioequivalence studies and regulatory approval.
2. What are the benefits of using vegetarian capsules for TESSALON?
Vegetarian capsules expand market access in regions and populations with dietary restrictions; they also improve perception among certain customer segments.
3. What excipient modifications can enable extended-release TESSALON?
Adding rate-controlling polymers (e.g., ethylcellulose) or applying special coatings can sustain drug release, subject to stability and regulatory validations.
4. Are there supply chain risks associated with supplying key excipients for TESSALON?
Yes. Gelatin and HPMC supply chains are vulnerable to raw material shortages, geopolitical issues, and contamination risks, impacting manufacturing continuity.
5. What regulatory considerations apply when changing excipients in TESSALON formulations?
Regulatory agencies require validation of safety, bioavailability, and stability for any excipient change, along with submission of updated data and labeling adjustments.
References
[1] U.S. Food and Drug Administration (FDA). (2022). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
[2] European Medicines Agency (EMA). (2021). Guideline on excipients in medicinal products.
[3] International Pharmaceutical Excipients Council (IPEC). (2020). Guidelines on excipient safety and quality.
[4] Kshirsagar, H. H., & Phadke, A. V. (2019). Advances in controlled release capsule formulations. Drug Development and Industrial Pharmacy.
